Rituximab for noninfectious uveitis

Developments in Ophthalmology

Volumn 51, Issue , 2012, Pages 98-109

  Miserocchi, Elisabett ^a   Modorati, Giulio ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY; RITUXIMAB;

ANIMAL; ARTICLE; B LYMPHOCYTE; BIOSYNTHESIS; CELLULAR IMMUNITY; DRUG EFFECT; HUMAN; IMMUNOLOGY; METABOLISM; UVEITIS;

ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; B-LYMPHOCYTES; HUMANS; IMMUNITY, CELLULAR; IMMUNOLOGIC FACTORS; UVEITIS;

EID: 84860847337     PISSN: 02503751     EISSN: 16622790     Source Type: Book Series    
DOI: 10.1159/000336188     Document Type: Article

References (55)

1. Blank M, Shoenfeld Y: B cell targeted therapy in autoimmunity. J Autoimmun 2007;28:62-68. (Pubitemid 46680498)
2. Perosa F, Favoino E, Caragnano MA, et al.: CD20: a target antigen for immunotherapy of autoimmune diseases. Autoimmun Rev 2005;4:526-531. (Pubitemid 41415764)
3. Reff ME, Carner K, Chambers KS, et al.: Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83:435-445.
4. Smolen JS, Keystone EC, Emery P, et al.: Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2007;66: 143-150. (Pubitemid 46226045)
5. Arkfeld DG: The potential utility of B cell-directed biologic therapy in autoimmune diseases. Rheumatol Int 2008;28:205-215. (Pubitemid 350265480)
6. Shaw T, Quan J, Totoritis MC: B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience. Ann Rheum Dis 2003;62:ii55-ii59.
7. De Vita S, Quartuccio L: Treatment of rheumatoid arthritis with rituximab: an update and possible indications. Autoimmun Rev 2006;5:443-448. (Pubitemid 44233403)
8. Kunkel L, Wong A, Maneatis T, et al.: Optimizing the use of rituximab for treatment of B-cell non-Hodgkin's lymphoma: a benefit-risk update. Semin Oncol 2000;27:53-61. (Pubitemid 32166264)
9. Edwards JC, Szczepanski I, Szczepanski J, et al.: Efficacy of B-cell targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;17:350.
10. Caporali R, Caprioli M, Bobbio-Pallavicini F, et al.: Long term treatment of rheumatoid arthritis with rituximab. Autoimmun Rev 2009;8:591-594.
11. Emery P, Fleishmann R, Filipowicz A, et al.: The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54:1390-1400.
12. Conti F, Perricone C, Ceccarelli F, Valesini G: Rituximab treatment of systemic lupus erythematosus in controlled trials and in clinical practice: two sides of the same coin. Autoimm Rev 2010;9: 716-720.
13. Stasi R, Stipa E, Del Poeta G, et al.: Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology 2006;45:1432-1436. (Pubitemid 44605482)
14. Eriksson P: Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J Intern Med 2005;257: 540-548. (Pubitemid 40776514)
15. Tobon GJ, Pers JO, Youinou P, Saraux A: B celltargeted therapies in Sjogren's syndrome. Autoimm Rev 2010;9:224-228.
16. Quartuccio L, Fabris M, Salvin S, et al.: Controversies on rituximab therapy in Sjogren syndromeassociated lymphoproliferation. Int J Rheumatol 2009;10:1-8.
17. Garcia-Carrasco M, Jimenez-Hernandez M, Escarcega RO, et al.: Use of rituximab in systemic lupus erythematosus: an update. Autoimmun Rev 2009;8:343-348.
18. Deans JP, Li H, Polyak MJ: CD20-mediated apoptosis: signalling through lipid rafts. Immunology 2002;107:176-182. (Pubitemid 35279043)
19. Kneitz C, Wilhelm M, Tony HP: Effective B cell depletion with rituximab in the treatment of autoimmune diseases. Immunobiology 2002;206:519-527. (Pubitemid 36192911)
20. Di Gaetano N, Cittera E, Nota R, et al.: Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 2003;171:1581-1587. (Pubitemid 36900094)
21. Zapata LF, Agudelo LM, Paulo JD, Pineda R: Sjogren keratoconjuntivitis sicca treated with rituximab. Cornea 2007;26:886-887. (Pubitemid 47220569)
22. Onal S, Kazokoglu H, Koc A, Yavuz S: Rituximab for remission induction in a patient with relapsing necrotizing scleritis associated with limited Wegener's granulomatosis. Ocul Immunol Inflamm 2008;16:230-232.
23. Ahmadi-Simab K, Lamprecht P, Nolle B, et al.: Successful treatment of refractory anterior scleritis in primary Sjogren's syndrome with rituximab. Ann Rheum Dis 2005;64:1087-1088. (Pubitemid 40909530)
24. Kurz PA, Suhler EB, Choi D, Rosenbaum JT: Rituximab for treatment of ocular inflammatory disease: a series of four cases. Br J Ophthalmol 2009; 93:546-548.
25. Taylor SRJ, Salama AD, Josjhi L, et al.: Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis. Arthritis Rheum 2009; 50:1540-1547.
26. Cheung CM, Murray PI, Savage CO: Successful treatment of Wegener's granulomatosis associated scleritis with rituximab. Br J Ophthalmol 2005;89: 1542. (Pubitemid 41527407)
27. Huerva V, Sanchez MC, Traveset A, et al.: Rituximab for peripheral ulcerative keratitis with Wegener granulomatosis. Cornea 2010;29:708-710.
28. Freidlin J, Wong IG, Acharya N: Rituximab treatment for peripheral ulcerative keratitis associated with Wegener's granulomatosis. Br J Ophthalmol 2007;91:1414. (Pubitemid 47492887)
29. Tappeiner C, Heinz C, Specker C, Heilighenhaus A: Rituximab as a treatment option for refractory endogenous anterior uveitis. Ophthalmic Res 2007; 39:184-186. (Pubitemid 46975985)
30. Heiligenhaus A, Miserocchi E, Heinz C, et al.: Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD monoclonal antibody (rituximab). Rheumatology 2011;50: 1390-1394.
31. Miserocchi E, Pontikaki I, Modorati G, et al.: Rituximab for uveitis. Ophthalmology 2011;118: 223-224.
32. Miserocchi E, Pontikaki I, Modorati G, et al.: Anti-CD monoclonal antibody (rituximab) treatment for inflammatory ocular diseases. Autoimm Rev 2011;11:35-39.
33. Davatchi F: New and innovative therapies for Behçet's disease. APLAR J Rheum 2004;7:141-145. (Pubitemid 41111083)
34. Davatchi F, Shams H, Rezaipoor M, et al.: Rituximab in intractable ocular lesions of Behcet's disease; randomized single-blind control study (pilot study). Int J Rheum Dis 2010;13:246-252.
35. Sadreddini S, Noshad H, Molaeefard M, Noshad R: Treatment of retinal vasculitis in Behcet's disease with rituximab. Mod Rheumatol 2008;18:306-308.
36. Hickman RA, Denniston AK, Yee CS, et al.: Bilateral retinal vasculitis in a patient with systemic lupus erythematosus and its remission with rituximab therapy. Lupus 2010;19:327-329.
37. Charteris DG, Barton K, McCartney AC, Lightman SL: CD4+ lymphocyte involvement in ocular Behcet's Diseases. Autoimmunity 1992;12:201-206.
38. Heiligenhaus A, Niewerth M, Ganser G, et al.: Prevalence and complications of uveitis in juvenile idiopahic arthritis in a population-based nationwide study in Germany: suggested modification of the current screening guidelines. Rheumatology 2007;46:1015-1059.
39. Thorne JE, Woreta F, Kedhar SR, et al.: Juvenile idiopathic arthritis-associated uveitis: incidence of ocular complications and visual acuity loss. Am J Ophthalmol 2007;143:840-846.
40. Miserocchi E, Baltatzis S, Ekong A, et al.: Efficacy and safety of chlorambucil in intractable noninfectious uveitis: the Massachusetts Eye and Ear Infirmary experience. Ophthalmology 2002;109:137-142. (Pubitemid 34027437)
41. Saurenmann RK, Levin AV, Rose JB, et al.: Tumour necrosis factor-α inhibitors in the treatment of childhood uveitis. Rheumatology 2006;45:982-989. (Pubitemid 44283053)
42. Rajaraman RT, Kimura Y, Li S, et al.: Retrospective case review of pediatric patients with uveitis treated with infliximab. Ophthalmology 2006;113:308-314. (Pubitemid 43170781)
43. Kitzmann AS, Pulido JS, Mohney BG, et al.: Intraocular use of rituximab. Eye 2007;21:1524-1527.
44. Ohguro N, Hashida N, Tano Y: Effect of intravitreous rituximab injections in patients with ocular lesions associated with central nervous system lymphoma. Arch Ophthalmol 2008;126:1002-1003. (Pubitemid 352008390)
45. Aries PM, Hellmich B, Voswinkel J, et al.: Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis 2006;65:853-858.
46. Cambridge G, Leandro MJ, Edwards JC, et al.: Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 2003;48:2146-2154. (Pubitemid 36959194)
47. Kimby E: Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 2005;31:456-473.
48. Fleischmann RM: Safety of biologic therapy in rheumatoid arthritis and other autoimmune diseases: focus on rituximab. Semin Arthritis Rheum 2009;38:265-280.
49. Tam C, Seymour JF, Brown M, et al.: Early and late infectious consequences of adding rituximab to fludarabine and cyclophosphamide in patients with indolent lymphoid malignancies. Haematologica 2005;90:700-702. (Pubitemid 40780897)
50. Kong JSW, Teuber SS, Gershwin ME: Potential adverse events with biologic response modifiers. Autoimm Rev 2006;5:471-485. (Pubitemid 44233405)
51. Salliot C, Dougados M, Gossec L: Risk of serious infections during rituximab, abatacept and anakinra therapies for rheumatoid arthritis: meta-analyses of randomized placebo-controlled trials. Ann Rheum Dis 2009;68:25-32.
52. Calabrese LH, Molloy ES: Progressive multifocal leucoencephalopathy in the rheumatic diseases: assessing the risks of biological immunosuppres sive ther apies. Ann Rheum Dis 2008;67(suppl 3): iii64-iii65.
53. Sera T, Hiasa Y, Michitaka K, et al.: Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab. Intern Med 2006;45: 721-724. (Pubitemid 44027603)
54. Popa C, Leandro MJ, Cambridge G, et al.: Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over years. Rheumatology 2007;46: 626-630. (Pubitemid 46523308)
55. Keystone E, Fleischmann R, Emery P, et al.: Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum 2007;56: 3896-3908. (Pubitemid 350262316)